trending Market Intelligence /marketintelligence/en/news-insights/trending/qMytLzPSmxLS83uRU5jEAQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Neos Therapeutics settles patent litigation against Actavis Laboratories

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Neos Therapeutics settles patent litigation against Actavis Laboratories

Neos Therapeutics Inc. granted Actavis Laboratories FL Inc. a license to market a generic version of its attention deficit hyperactivity disorder drug as part of a settlement agreement.

Neos had filed a patent litigation against the Teva Pharmaceutical Industries Ltd. unit after it sought U.S. Food and Drug Administration approval to introduce a generic version of Adzenys XR-ODT.

Under the settlement, Actavis Laboratories can market its generic drug starting Sept. 1, 2025, or earlier, under certain circumstances.

The agreement is subject to the approval of the Federal Trade Commission and the U.S. Department of Justice.